KOL Perception on Cardiometabolic Conditions and Recent Advancements: Insights from 50 Key Opinion Leaders Across the United States and Europe
A Cardiometabolic KOL Perception Study exploring cardiometabolic disease management, GLP-1 receptor agonists, dual and triple incretin therapies, cardio-kidney-metabolic care, precision medicine, AI in cardiometabolic care, digital health technologies, and future treatment strategies across the United States and Europe.
Introduction
Cardiometabolic Treatment Landscape
Cardiometabolic disease remains one of the greatest global healthcare challenges, with obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, hypertension, and metabolic syndrome driving substantial morbidity, mortality, and healthcare costs worldwide. Despite major therapeutic breakthroughs, effective cardiometabolic disease management continues to face barriers including delayed diagnosis, residual cardiovascular risk, treatment adherence, affordability, and equitable access to innovative therapies.
To better understand evolving cardiometabolic treatment trends, emerging innovations, and future opportunities, SPER Market Research conducted a comprehensive Cardiometabolic KOL Study involving 50 Key Opinion Leaders across the United States and Europe. This healthcare market research initiative captures clinical expert insights and healthcare expert opinion on emerging therapies, cardio-kidney-metabolic care, precision medicine, AI-driven healthcare, and future treatment strategies.
The findings highlight growing confidence in GLP-1 receptor agonists, dual incretin therapy, triple incretin therapy, biomarker-guided therapy, personalized medicine, and integrated CKM care model approaches. Experts also emphasized that improving affordability, patient adherence, early risk identification, and access to advanced therapies will remain central priorities for the future of cardiometabolic care.
Primary Objective
To assess expert perceptions regarding current cardiometabolic disease management, emerging therapies, unmet needs, precision medicine, integrated cardio-kidney-metabolic care, digital health technologies, AI integration, and future treatment strategies.
Respondent Profile
This study provides directional cardiometabolic market intelligence on unmet needs, GLP-1 receptor agonists, dual and triple incretin therapies, CKM care, biomarker-guided therapy, AI clinical decision support, remote patient monitoring, digital therapeutics, and future cardiometabolic innovation.
Key Outcome Summary
What Cardiometabolic KOLs Highlighted
Disease Burden
Strong consensus that cardiometabolic disease continues to impose a substantial global healthcare burden despite therapeutic progress.
Therapy Innovation
High enthusiasm for GLP-1 receptor agonists, dual incretin therapy, triple incretin therapy, and cardiometabolic risk reduction strategies.
Precision Future
Increasing emphasis on preventive healthcare, early risk identification, personalized medicine, and integrated CKM care model delivery.
Digital Health
Growing adoption of AI in cardiometabolic care, AI clinical decision support, remote patient monitoring, wearable health technology, and digital therapeutics.
Survey Results Summary
Cardiometabolic KOL Survey Results
| Q# | Survey Question | Primary Objective | Most Common Response | % of KOLs |
|---|---|---|---|---|
| 1 | How significant is the current unmet need in cardiometabolic disease management? | Assess disease burden | Very High / High unmet need | 82% |
| 2 | Are current therapies adequately reducing long-term cardiometabolic risk? | Evaluate current treatments | Partially adequate but insufficient | 74% |
| 3 | What has been the most transformative advancement in cardiometabolic care over the past five years? | Identify innovations | GLP-1 receptor agonists, dual/triple incretin therapies | 72% |
| 4 | How important is early risk identification and preventive intervention? | Evaluate prevention | Extremely important | 90% |
| 5 | Will precision medicine become standard practice? | Understand expectations | Yes | 76% |
| 6 | What is the greatest barrier to optimal cardiometabolic care? | Identify challenges | Limited access and affordability | 60% |
| 7 | How likely are AI and digital health technologies to improve cardiometabolic management? | Evaluate technology | Likely / Very likely | 78% |
| 8 | How optimistic are you about future cardiometabolic treatment outcomes? | Assess outlook | Optimistic / Very optimistic | 86% |
Detailed Response Distribution
Detailed Findings from the Cardiometabolic KOL Perception Study
KOLs reported substantial unmet need across cardiometabolic care despite major treatment advances.
- 82% of KOLs reported very high or high unmet need.
- Persistent challenges include early diagnosis, residual cardiovascular risk, adherence, affordability, and access.
Most experts see current therapies as helpful but not sufficient to reduce long-term risk for many patients.
- 74% selected partially adequate but insufficient.
- Experts emphasized the need for comprehensive cardiometabolic risk reduction and integrated care.
GLP-1 receptor agonists and dual/triple incretin therapies were identified as the leading innovation.
- 72% selected GLP-1 receptor agonists and dual/triple incretin therapies.
- This highlights the impact of next-generation therapies on obesity, diabetes, cardiovascular, and renal outcomes.
Early risk identification and preventive intervention were overwhelmingly viewed as critical to outcomes.
- 90% selected extremely important.
- Preventive healthcare can help reduce cardiovascular events, slow disease progression, and improve long-term cardiometabolic health.
KOLs expect precision medicine and biomarker-guided therapy to become increasingly routine.
- 76% believe precision medicine will become standard practice.
- This supports wider use of biomarker-guided therapy, genomic profiling, multi-omics, and individualized risk prediction.
Limited access and affordability remain the leading barriers to optimal cardiometabolic care.
- 60% identified limited access and affordability as the greatest barrier.
- Improved access, adherence support, and multidisciplinary CKM care pathways remain essential.
AI and digital health technologies are expected to improve cardiometabolic management.
- 78% said AI and digital health technologies are likely or very likely to improve management.
- Use cases include AI clinical decision support, AI-powered cardiometabolic risk prediction, remote patient monitoring, wearable health technology, and real-world evidence analytics.
Experts remain highly optimistic about future cardiometabolic treatment outcomes.
- 86% were optimistic or very optimistic about future outcomes.
- Optimism is linked to next-generation incretin therapies, precision medicine, CKM care models, AI, and digital health technologies.
Future Outlook
Cardiometabolic Future Trends
KOLs anticipate a transition toward personalized, prevention-focused cardiometabolic care that integrates advanced biomarkers, multi-omics, genetic profiling, AI-powered cardiometabolic risk prediction, digital health in cardiometabolic care, continuous remote patient monitoring, and real-world evidence. These innovations are expected to improve cardiovascular, renal, and metabolic outcomes while enabling personalized cardiometabolic treatment strategies.
Experts also expect rapid adoption of GLP-1 receptor agonists, dual incretin therapy, and triple incretin therapy, alongside broader recognition of obesity as a chronic disease requiring long-term obesity treatment innovation. The future of cardiometabolic care will likely be shaped by integrated cardio-kidney-metabolic care, AI clinical decision support, wearable health technology, digital therapeutics, and stronger use of healthcare strategic intelligence to support data-driven decision-making.
Conclusion
Overall Study Conclusion
This KOL Perception Study demonstrates that the future of cardiometabolic disease management is rapidly evolving through advances in precision medicine, integrated cardio-kidney-metabolic care, next-generation incretin therapies, and AI in cardiometabolic care.
According to this cardiometabolic expert opinion study, healthcare leaders believe that combining biomarker-guided therapy, predictive analytics, real-world evidence, and multidisciplinary care will significantly improve long-term cardiometabolic health while accelerating cardiometabolic risk reduction across diverse patient populations.
The findings further suggest that organizations investing in healthcare strategic intelligence, pharmaceutical market intelligence, and healthcare competitive intelligence will be better equipped to deliver personalized, preventive, and data-driven care. As cardiometabolic disease innovation continues to accelerate, integrated care models supported by AI and digital technologies will shape the future of cardiometabolic care.
FAQs
Frequently Asked Questions
What are cardiometabolic diseases?
Cardiometabolic diseases include obesity, cardiovascular disease, type 2 diabetes management challenges, chronic kidney disease management, hypertension, and metabolic disorders that significantly increase long-term health risks.
Why are GLP-1 receptor agonists transforming cardiometabolic care?
GLP-1 therapies for cardiometabolic disease improve blood glucose control, support weight loss, reduce cardiovascular events, and provide renal protection, making them one of the biggest breakthroughs in modern cardiometabolic care.
What is integrated cardio-kidney-metabolic care?
Integrated cardio-kidney-metabolic care is a multidisciplinary CKM care model that brings together cardiology, nephrology, endocrinology, and primary care to improve patient outcomes across interconnected diseases.
How is artificial intelligence improving cardiometabolic disease management?
AI in cardiometabolic disease management enables AI clinical decision support, AI-powered cardiometabolic risk prediction, remote patient monitoring, predictive analytics, personalized treatment recommendations, and improved patient engagement using real-world evidence.
What role does precision medicine play in cardiometabolic diseases?
Precision medicine for cardiometabolic diseases combines biomarker-guided therapy, genomic profiling, multi-omics, and individualized risk prediction to optimize treatment decisions for each patient.
Why is early intervention important in cardiometabolic disease?
Early risk identification and preventive healthcare reduce cardiovascular events, slow disease progression, improve patient outcomes, and strengthen long-term cardiometabolic health.
What are the biggest barriers to optimal cardiometabolic care?
Major challenges include affordability, delayed diagnosis, fragmented care, poor adherence, healthcare disparities, and limited access to advanced therapies that support comprehensive cardiometabolic disease management.
What trends will shape the future of cardiometabolic care?
The future of cardiometabolic care will be driven by GLP-1 receptor agonists, precision medicine, digital health technologies, wearable health technology, remote monitoring for cardiometabolic patients, AI clinical decision support, integrated cardio-kidney-metabolic care, and greater use of real-world evidence.
